Navigation Links
SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Date:2/26/2008

New Products for Medical Professionals, Hospital and Managed Care

Facilities

NEW YORK, February 26 /PRNewswire-FirstCall/ -- SPO Medical Inc. (SPOM)( http://finance.yahoo.com/q?s=SPOM.OB), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced its first commercial shipments of its recently announced professional pulse oximeters; the PulseOx 6000(TM) and PulseOx 6100(TM).

At the end of the fourth quarter 2007, SPO Medical introduced these two new professional products at the 53rd Annual International Respiratory Congress of the American Association for Respiratory Care (AARC) in Orlando, Florida and at the 39th MEDICA World Forum for Medicine in Dusseldorf, Germany.

The PulseOx 6000(TM) (finger device) and PulseOx 6100(TM) (hand-held device) are both designed for medical professionals, hospitals and managed care facilities. Based on SPO Medical' proprietary patented algorithms, both the PulseOx 6000(TM) and PulseOx 6100(TM) use Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation and heart rate. In addition, these devices utilize the new SPO Medical AutoSpot(TM) technology for accurate measurements even with patients that suffer from low perfusion.

SPO Medical's focus for these products is the professional medical market. Since the announcement of these new products, an order backlog has been building in the Company's major markets, the United States and European countries. Within the United States, SPO Medical will be targeting Hospital GPO's (General Purchasing Organizations) which service thousands of hospital establishments. In addition, the Company will be targeting large medical equipment distributors which service Outpatient Surgery Centers, Integrated Healthcare Delivery Networks and Federal Government facilities.

"Three months ago, we announced the PulseOx 6000(TM) and PulseOx 6100(TM) products; since then, orders have been building in all our major markets," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "This marks SPO Medical's first entree into the professional healthcare market, after developing a solid reputation over the last three years in the homecare market. These new products further demonstrate our long-term strategy of adapting SPO Medical's patented technology platform to new applications, which provide healthcare service providers and consumers with cost-effective life-enhancing information."

About SPO Medical

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. We undertake no obligation to revise or update any forward-looking statement for any reason.

SPO Medical Contact:

Michael Braunold, President & CEO

info@spomedical.com

+1-805-823-8163

Target 3 Communications Contact:

Jerry Cahn, Ph.D., J.D., President

jerry@target3.com

+1-646-827-0009


'/>"/>
SOURCE SPO Medical equipment Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
2. CIGNA Medical Group Selects Allscripts for Electronic Health Record
3. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
4. B-Line Medical and Immersion Medical Announce Partnership
5. MIT researcher addresses biomedical engineering challenges
6. Eklin Medical Reports Record Revenues for 2007
7. Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients
8. Symmetry Medical Reports Preliminary Fourth Quarter Revenue
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
11. Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):